Boteng Biology Announces Strategic Client Partnership Ceremony to Advance the Gene and Cell Therapy Industry

SUZHOU, China, Sept. 29, 2021 /PRNewswire/ -- On Sept. 26, the "Porton Biologics Strategic Clients Centralized Signing Ceremony" was grandly held.。Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd.、HKND YB1 PHARMACEUTICAL LIMITED、Nanjing CART Medical Technologies, Ltd、Suzhou Weiyou Gene Biotechnology Co., Ltd.、CNMDICR BIOPHARMA# Five Leading Companies in Gene and Cell TherapyStrategic Partnership Signed with Porton Biologics, a perfect partnership joining forces to jointly shape the future of the gene and cell therapy industry.

Ju Nianfeng, Chairman of Porton Pharma Solutions and CEO of Porton Biologics, delivered the opening remarks. Ju Nianfeng highlighted the development of three core capabilities: "From an overall strategic perspective, Porton Biologics will focus on establishing a global, end-to-end gene and cell therapy CDMO service platform, encompassing end-to-end capabilities spanning from IIT to IND to NDA, as well as from plasmids to viral vectors to cell therapies. This constitutes our first core capability. Second, we will focus on building an open, innovative, broad, and deep technology platform. Third, we will establish an excellent project operation and manufacturing operation system."

Ju Nianfeng stated, "The ultimate goal of developing the three core capabilities is to create value for our customers. We will steadfastly align with our value proposition to deliver fast, high-quality, efficient, and reliable solutions. We extend our sincere gratitude to our five strategic clients—BoShengJi Medicine Science and Technology (Suzhou) Co., Ltd., HKND YB1 PHARMACEUTICAL LIMITED, Nanjing CART Medical Technologies, Ltd., Suzhou Weiyou Gene Biotechnology Co., Ltd., and CNMDICR BIOPHARMA—for their trust in Porton Biologics Ltd. We wish these five outstanding clients every success as they ride the surging tide of gene and cell therapy and forge ahead with unwavering momentum."。”

Porton Biologics&Biosgen

Boshengji and Porton Biologics RegardingA strategic partnership was reached in the large-scale lentiviral manufacturing process for the CAR-T cell project.

Yang Lin, CEO of BoShengJi Medicine Science and Technology (Suzhou) Co., Ltd., stated, "BoShengJi is primarily engaged in the R&D of novel CAR-T cell therapies. We currently have two IND applications approved: one is a CD19-CAR-T, and the other is the world's first original CD7-CAR-T for the treatment of leukemia. Independent innovation is crucial, and we aspire to better benefit patients in China and globally. While BoShengJi is committed to building a comprehensive full-chain ecosystem from plasmids to viral vectors to cells, we are highly eager to collaborate with high-quality CDMO companies such as Porton Biologics Ltd., which will enable our business to grow faster and more robustly."

Porton Biologics& HKND YB1

HKND YB1 Pharmaceutical and Porton Biologics Jointly Advance Oncolytic BacteriaA strategic partnership has been established regarding the YB1 project, including dual China-US regulatory submissions for CMC and IND registration.

Yu Bin, Chief Scientist at HKND YB1 Pharmaceutical, stated, "This collaboration holds significant importance for the development of novel oncolytic vectors, including oncolytic bacteria. We also hope it will provide new guidance for cancer treatment strategies for all of humanity."

“HKND YB1 PHARMACEUTICAL LIMITED focuses on the development of cancer immunotherapies, gene therapies, and various innovative drugs, and is committed to delivering revolutionary immunotherapy solutions worldwide. Our first vector platform, YB1, has already demonstrated significant efficacy in clinical studies of primary cancers in pets. We are eager to collaborate with the passionate and creative scientists at Porton Biologics Ltd. to jointly advance the YB1 oncolytic bacteria project. We also look forward to exploring targeted therapies for solid tumors, and through our future cooperation, we aim to reach new heights and achieve our shared goals of long-term mutual benefit, win-win collaboration, and joint development.”

Porton Biologics& Nanjing CART

Nanjing CART and Porton Biologics on mesothelin (establish a long-term and close strategic research and development partnership for multiple CAR-T projects, including the Mesothelin) CAR-T project and B7-H3 CAR-T project.

Wang Enxiu, CEO of Nanjing CART, stated, "Nanjing CART focuses on solid tumor CAR-T therapy. We indeed pioneered the design of solid tumor-targeting CAR-T at the earliest stage and have accumulated extensive experience. Our work centers on the very core of CAR-T—signal activation. Once activated, it will yield a broad product pipeline targeting various indications."

“We have a very clear understanding of the company. The pathway from technology to product needs to be clearly delineated. In this process, Porton Biologics and Nanjing CART discovered each other. Our willingness to establish a strategic partnership with Porton is primarily based on two factors: First, the technical expertise of Porton Biologics; we have had in-depth and constructive exchanges with the technical leads across all stages of CMC. Second, Porton’s flexibility and versatility empower enterprises. Porton Biologics empowers Nanjing CART, Nanjing CART empowers T cells, and T cells empower patients. Therefore, we are pursuing a shared mission. We hope that following this signing ceremony, we will forge a long-term, highly efficient, and friendly strategic partnership.”

Porton Biologics& Weiyou Gene

Suzhou Weiyou Gene Biotechnology Co., Ltd. and Porton Biologics Ltd. have entered into a strategic partnership covering the end-to-end process for AAV gene therapy vectors, from technology development to large-scale manufacturing processes and quality analysis.

Suzhou Weiyou Gene Biotechnology Co., Ltd. is one of the very few gene therapy companies in China with targeted and regulatable capabilities. Dedicated to developing gene therapies for a variety of rare and chronic diseases, the company has completed in vitro and in vivo studies across multiple indications and is poised to enter the clinical trial phase.

Wei Jiye, Chairman of Weiyou Gene, stated, "Weiyou Gene and Porton Biologics share a profound connection, and we believe this collaboration will advance the development of gene therapy drugs for ophthalmic diseases."

Porton Biologics& CNMDICR BIOPHARMA

CNMDICR Biopharma and Porton Biologics Ltd. have entered into an end-to-end strategic partnership covering large-scale manufacturing processes and quality analysis for multiple gene therapy programs targeting rare genetic diseases.

"CNMDICR BIOPHARMA focuses on developing gene therapy drugs. In addition to lentiviral vectors, we are also developing in vivo genome repair using AAV vectors, specifically a nuclease-independent genome repair approach.”

Dong Wenji, Founder of CNMDICR BIOPHARMA, stated, “In the transition from the preclinical to clinical stage, whether for IITs or formal clinical trials, we will require support from Porton Biologics Ltd. We began utilizing the insect baculovirus system for AAV production at a very early stage. It is highly encouraging news for the gene therapy sector that Porton Biologics Ltd. has successfully recruited a leading expert like Dr. Sander van Deventer to China. Our current projects are still in their early phases, and we hope that through our partnership with Porton Biologics Ltd., we can accelerate the industrialization and commercialization of our insect baculovirus-based AAV production.”